<?xml version='1.0' encoding='utf-8'?>
<document id="24676085"><sentence text="DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells." /><sentence text="DNA methylation is an epigenetic phenomenon known to play an important role in the development and progression of human cancer" /><sentence text=" Enzyme responsible for this process is DNA methyltransferase 1 (DNMT1) that maintains an altered methylation pattern by copying it from parent to daughter DNA strands after replication" /><sentence text=" Aberrant methylation of the promoter regions of genes critical for normal cellular functions is potentially reversible" /><sentence text=" Therefore, inactivation of DNMT1 seems to be a valuable target for the development of cancer therapies" /><sentence text=" Currently, the most popular DNMT inhibitors (DNMTi) are cytidine analogues like 5-azacytidine, 5-aza-2'-deoxycytidine (decitabine) and pyrimidin-2-one ribonucleoside (zebularine)"><entity charOffset="57-65" id="DDI-PubMed.24676085.s6.e0" text="cytidine" /><entity charOffset="81-94" id="DDI-PubMed.24676085.s6.e1" text="5-azacytidine" /><entity charOffset="96-118" id="DDI-PubMed.24676085.s6.e2" text="5-aza-2'-deoxycytidine" /><entity charOffset="120-130" id="DDI-PubMed.24676085.s6.e3" text="decitabine" /><entity charOffset="136-166" id="DDI-PubMed.24676085.s6.e4" text="pyrimidin-2-one ribonucleoside" /><entity charOffset="168-178" id="DDI-PubMed.24676085.s6.e5" text="zebularine" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e0" e2="DDI-PubMed.24676085.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e0" e2="DDI-PubMed.24676085.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e0" e2="DDI-PubMed.24676085.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e0" e2="DDI-PubMed.24676085.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e0" e2="DDI-PubMed.24676085.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e0" e2="DDI-PubMed.24676085.s6.e5" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e1" e2="DDI-PubMed.24676085.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e1" e2="DDI-PubMed.24676085.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e1" e2="DDI-PubMed.24676085.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e1" e2="DDI-PubMed.24676085.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e1" e2="DDI-PubMed.24676085.s6.e5" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e2" e2="DDI-PubMed.24676085.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e2" e2="DDI-PubMed.24676085.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e2" e2="DDI-PubMed.24676085.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e2" e2="DDI-PubMed.24676085.s6.e5" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e3" e2="DDI-PubMed.24676085.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e3" e2="DDI-PubMed.24676085.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e3" e2="DDI-PubMed.24676085.s6.e5" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e4" e2="DDI-PubMed.24676085.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24676085.s6.e4" e2="DDI-PubMed.24676085.s6.e5" /></sentence><sentence text=" In colorectal cancer, epigenetic modifications play an essential role at each step of carcinogenesis" /><sentence text=" Therefore, we have addressed the hypothesis that DNA methyltransferase inhibitors may potentiate inhibitory effects of classical chemotherapeutic agents, such as oxaliplatin and 5-fluorouracil (5-FU), commonly used in colorectal cancer therapy"><entity charOffset="163-174" id="DDI-PubMed.24676085.s8.e0" text="oxaliplatin" /><entity charOffset="179-193" id="DDI-PubMed.24676085.s8.e1" text="5-fluorouracil" /><entity charOffset="195-199" id="DDI-PubMed.24676085.s8.e2" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.24676085.s8.e0" e2="DDI-PubMed.24676085.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24676085.s8.e0" e2="DDI-PubMed.24676085.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24676085.s8.e0" e2="DDI-PubMed.24676085.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s8.e1" e2="DDI-PubMed.24676085.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24676085.s8.e1" e2="DDI-PubMed.24676085.s8.e2" /></sentence><sentence text=" Here, our report shows that DNMTi can have positive interactions with standard chemotherapeutics in colorectal cancer treatment" /><sentence text=" Using pharmacological models for the drug-drug interaction analysis, we have revealed that the combination of decitabine with 5-FU or oxaliplatin shows the most attractive interaction (synergism), whereas the effect of zebularine in combinations with chemotherapeutics is moderate and may be depended on genetic/epigenetic background of a cell line or secondary drug used in combination"><entity charOffset="111-121" id="DDI-PubMed.24676085.s10.e0" text="decitabine" /><entity charOffset="127-131" id="DDI-PubMed.24676085.s10.e1" text="5-FU" /><entity charOffset="135-146" id="DDI-PubMed.24676085.s10.e2" text="oxaliplatin" /><entity charOffset="220-230" id="DDI-PubMed.24676085.s10.e3" text="zebularine" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e0" e2="DDI-PubMed.24676085.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e0" e2="DDI-PubMed.24676085.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e0" e2="DDI-PubMed.24676085.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e0" e2="DDI-PubMed.24676085.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e1" e2="DDI-PubMed.24676085.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e1" e2="DDI-PubMed.24676085.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e1" e2="DDI-PubMed.24676085.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e2" e2="DDI-PubMed.24676085.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24676085.s10.e2" e2="DDI-PubMed.24676085.s10.e3" /></sentence><sentence text=" Our results suggest that DNMTi administered in combination with standard chemotherapeutics might improve the treatment of patients with colorectal cancers" /><sentence text=" " /></document>